Literature DB >> 20720561

Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.

Eva M Murauer1, Yannick Gache, Iris K Gratz, Alfred Klausegger, Wolfgang Muss, Christina Gruber, Guerrino Meneguzzi, Helmut Hintner, Johann W Bauer.   

Abstract

Functional defects in type VII collagen, caused by premature termination codons on both alleles of the COL7A1 gene, are responsible for the severe autosomal recessive types of the skin blistering disease, recessive dystrophic epidermolysis bullosa (RDEB). The full-length COL7A1 complementary DNA (cDNA) is about 9 kb, a size that is hardly accommodated by therapeutically used retroviral vectors. Although there have been successful attempts to produce functional type VII collagen protein in model systems of RDEB, the risk of genetic rearrangements of the large repetitive cDNA sequence may hamper the clinical application of full-length COL7A1 cDNA in the human system. Therefore, we used trans-splicing to reduce the size of the COL7A1 transcript. Retroviral transduction of RDEB keratinocytes with a 3' pre-trans-splicing molecule resulted in correction of full-length type VII collagen expression. Unlike parental RDEB keratinocytes, transduced cells displayed normal morphology and reduced invasive capacity. Moreover, transduced cells showed normal localization of type VII collagen at the basement membrane zone in skin equivalents, where it assembled into anchoring fibril-like structures. Thus, using trans-splicing we achieved correction of an RDEB phenotype in vitro, which marks an important step toward its application in gene therapy in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20720561     DOI: 10.1038/jid.2010.249

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  35 in total

Review 1.  MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction.

Authors:  Verena Behrens-Gawlik; Giulia Mearini; Christina Gedicke-Hornung; Pascale Richard; Lucie Carrier
Journal:  Pflugers Arch       Date:  2013-12-12       Impact factor: 3.657

2.  The design and optimization of RNA trans-splicing molecules for skin cancer therapy.

Authors:  Christina Gruber; Ulrich Koller; Eva M Murauer; Stefan Hainzl; Clemens Hüttner; Thomas Kocher; Andrew P South; Helmut Hintner; Johann W Bauer
Journal:  Mol Oncol       Date:  2013-08-19       Impact factor: 6.603

Review 3.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

4.  CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Gregory H Reaman; Lloyd G Mitchell
Journal:  Integr Biol (Camb)       Date:  2015-02       Impact factor: 2.192

Review 5.  Gene therapy for skin diseases.

Authors:  Emily Gorell; Ngon Nguyen; Alfred Lane; Zurab Siprashvili
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 6.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 7.  Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Authors:  Christopher Perdoni; Mark J Osborn; Jakub Tolar
Journal:  Transl Res       Date:  2015-05-27       Impact factor: 7.012

Review 8.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 9.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

Review 10.  Basement membranes in the cornea and other organs that commonly develop fibrosis.

Authors:  Paramananda Saikia; Carla S Medeiros; Shanmugapriya Thangavadivel; Steven E Wilson
Journal:  Cell Tissue Res       Date:  2018-10-03       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.